The estimated Net Worth of Capital Management, Llc Kol... is at least $74.5 Million dollars as of 24 April 2009. Capital Kol owns over 15,759 units of Biospecifics Technologies stock worth over $74,507,114 and over the last 16 years Capital sold BSTC stock worth over $0.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Capital Kol BSTC stock SEC Form 4 insiders trading
Capital has made over 4 trades of the Biospecifics Technologies stock since 2009, according to the Form 4 filled with the SEC. Most recently Capital bought 15,759 units of BSTC stock worth $306,513 on 24 April 2009.
The largest trade Capital's ever made was buying 15,759 units of Biospecifics Technologies stock on 24 April 2009 worth over $306,513. On average, Capital trades about 6,828 units every 9 days since 2008. As of 24 April 2009 Capital still owns at least 841,603 units of Biospecifics Technologies stock.
You can see the complete history of Capital Kol stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Insiders trading at Biospecifics Technologies
Over the last 33 years, insiders at Biospecifics Technologies have traded over $67,860,045 worth of Biospecifics Technologies stock and bought 7,761,661 units worth $656,708,120 . The most active insiders traders include Capital Management, Llc Kol..., International Plc Endo, and Max Link. On average, Biospecifics Technologies executives and independent directors trade stock every 73 days with the average trade being worth of $6,538,649. The most recent stock trade was executed by International Plc Endo on 2 December 2020, trading 7,344,955 units of BSTC stock currently worth $650,028,518.
What does Biospecifics Technologies's logo look like?
Complete history of Capital Kol stock trades at Biospecifics Technologies
Biospecifics Technologies executives and stock owners
Biospecifics Technologies executives and other stock owners filed with the SEC include:
-
Jennifer Chao,
Independent Chairman of the Board -
Michael Schamroth,
Independent Director -
Paul Gitman,
Independent Director -
Mark Wegman,
Director -
Toby Wegman,
Director -
Sarah McCabe,
Stern Investor Relations -
Michael Sherman,
Independent Director -
Corey Fishman,
Independent Director -
Alex Monteith,
Senior Vice President and Chief Business Officer -
Patrick Hutchison,
Chief Financial Officer -
Joseph Truitt,
Chief Executive Officer, Director -
Jeffrey Kenneth Vogel,
-
Jyrki Mattila,
Director -
Thomas Wegman,
President -
Of Edwin H. Wegman Estate,
10% owner -
Patrick M Caldwell,
Principal Financial Officer -
Partners Lp Bio,
10% owner -
Albert Horcher,
-
Lawrence Dobroff,
CFO -
Max Link,
Director -
Henry Morgan,
Director -
George M Gould,
Director -
Matthew Geller,
Director -
Capital Management, Llc Kol...,
-
Capital Management, Llcra C...,
-
Capital Management, Llcaldr...,
-
Capital Management, Llc Kol...,
-
Capital Management, Llcra C...,
-
J Kevin Buchi,
Chief Executive Officer -
International Plc Endo,
10% owner